Sulforaphane & Cancer: What Human Clinical Trials Actually Show

Sulforaphane has real human cancer research, but it is not an established cancer treatment or proven cancer-prevention therapy. Human trials include prostate-cancer studies, breast and pancreatic research, melanoma-related prevention work and a 12-month lung-risk trial in former smokers. The problem is that most positive findings involve molecular markers, tissue gene expression or surrogate endpoints rather than recurrence, metastasis, cancer incidence or survival.

That distinction matters because sulforaphane has compelling anticancer mechanisms in cells and animals. Human evidence is the harder test.

What do randomized human cancer trials show?

Prostate cancer: the most developed human evidence base

One Phase II study gave men with recurrent prostate cancer a sulforaphane-rich broccoli sprout extract providing 200 µmol/day of sulforaphane. The prespecified primary endpoint was a 50% or greater PSA decline. Only one participant met that threshold, so the primary endpoint failed.^[1]

Seven men had smaller PSA declines and PSA doubling time lengthened during treatment. Those are potentially interesting signals, but a small single-arm study cannot establish that sulforaphane slowed cancer progression.

The ESCAPE randomized trial approached prostate cancer differently. Men on active surveillance consumed standard or glucoraphanin-enriched broccoli soup for 12 months. Higher-glucoraphanin broccoli attenuated changes in several potentially oncogenic prostate-tissue gene-expression pathways.^[2]

Editorial interpretation: prostate tissue appears biologically responsive to glucoraphanin-rich broccoli interventions, but neither trial demonstrates that a supplement prevents metastasis, avoids surgery or prolongs survival.

What does the randomized-trial systematic review conclude?

A 2023 systematic review using Cochrane methods identified eight randomized sulforaphane trials across prostate, breast, pancreatic cancer and melanoma settings.^[3]

Some molecular, histological and gene-expression endpoints moved in a potentially favorable direction. Others did not. Prostate PSA findings were inconsistent, and a pancreatic-cancer survival signal was not statistically significant. Differences in cancer type, formulation, dose and endpoints were too large for a meaningful meta-analysis.

Bottom-line conclusion from the review: the evidence is promising enough for continued research, but insufficient to establish sulforaphane as cancer therapy.

What does the 2026 systematic review change?

A broader 2026 systematic review synthesized 118 studies: 17 clinical trials, 31 observational studies and 70 preclinical investigations.^[5] It extends the evidence map through newer clinical work, including the former-smoker Phase II trial, while also reviewing epigenetic and PRMT5–MEP50 mechanisms.

The larger paper count should not be mistaken for stronger clinical proof. Much of the database is observational or preclinical, and many human findings remain biomarker or surrogate endpoints. The review calls for adequately powered prevention trials with clinical endpoints before chemopreventive efficacy can be established.

Editorial interpretation: the 2026 review strengthens the case that sulforaphane deserves continued cancer-prevention research. It does not establish that taking a sulforaphane supplement prevents cancer or treats established disease.

Lung-cancer-risk research: a positive Ki-67 signal does not equal cancer prevention

A 2025 randomized Phase II trial followed former smokers at high risk for lung cancer for 12 months and used paired bronchial biopsies. Sulforaphane significantly reduced Ki-67, a marker of cellular proliferation, compared with placebo.^[4]

But bronchial histopathology did not significantly improve, and apoptosis markers including caspase-3 and TUNEL were not significantly changed. No severe adverse events were observed.

This is exactly the kind of study that can be distorted in marketing. “Reduced a proliferation biomarker” is accurate. “Prevents lung cancer” is not.

What about tobacco carcinogen detoxification?

A randomized crossover trial in current smokers found that a higher dose of Avmacol increased urinary detoxification biomarkers for benzene, acrolein and crotonaldehyde.^[6] That is relevant to carcinogen metabolism, but it is still a biomarker study rather than a cancer-incidence trial.

See our dedicated sulforaphane detoxification guide for the pollution and smoking biomarker evidence.

Is sulforaphane being studied for cancer prevention now?

Yes. The U.S. National Cancer Institute continues to list sulforaphane as an intervention in prevention research, including active studies in high-risk populations. Ongoing trials are evidence that researchers consider the mechanism worth testing—not evidence that prevention has already been proven.

That distinction is especially important for people at elevated cancer risk. A biologically plausible intervention should not displace screening, risk-reduction surgery when indicated, smoking cessation, sun protection, vaccination, or other established preventive measures.

Why is sulforaphane interesting to cancer researchers?

Preclinical work links sulforaphane to several processes relevant to carcinogenesis:

• KEAP1–NRF2 stress-response signaling
• Phase II xenobiotic-metabolism enzymes
• Histone deacetylase activity
• Cell-cycle arrest and apoptosis in some tumor models
• Inflammatory signaling
• Detoxification of selected environmental carcinogens

These mechanisms explain why sulforaphane is studied. They do not establish that activating or modifying those pathways will improve a patient's cancer outcome.

Does more bioavailable sulforaphane mean better anticancer efficacy?

Not automatically. Higher or more reliable systemic exposure gives an intervention a better chance of engaging its biological targets. But bioavailability is a delivery result, not a cancer outcome.

Our sulforaphane bioavailability guide explains how myrosinase, precursor form and delivery design affect exposure. Those pharmacokinetic differences should not be converted into cancer-treatment claims without outcome trials.

Can someone with cancer take a sulforaphane supplement?

That is a clinical question, not a general supplement recommendation. People receiving chemotherapy, immunotherapy, radiation, targeted therapy or perioperative treatment should discuss concentrated sulforaphane products with their oncology team. Mechanistic antioxidant, redox and enzyme effects could be relevant to treatment context, and human interaction data are incomplete.

Do not replace or delay evidence-based cancer treatment with sulforaphane, broccoli sprouts or any supplement.

Bottom line

Sulforaphane has legitimate human oncology research, but the current evidence does not establish it as a cancer treatment or proven cancer-prevention supplement. Prostate trials show molecular and PSA-related signals but important limitations. The 2025 former-smoker trial changed Ki-67 without improving its other major tissue endpoints. The 2023 RCT-focused review found heterogeneous results insufficient for therapeutic conclusions, and the broader 2026 systematic review still calls for larger trials with clinical prevention endpoints.

The scientifically interesting story is real. The treatment and prevention claims are not established.